About Humacyte
Humacyte is a company based in Morrisville (United States) founded in 2004. It operates as a HealthTech and Product-as-a-Service. Humacyte has raised $424.76 million across 11 funding rounds from investors including SVB, Bangkok Bank and Fresenius Medical Care. The company has 220 employees as of December 31, 2024. Humacyte offers products and services including Symvess™ and Acellular Tissue Engineered Vessel (ATEV™). Humacyte operates in a competitive market with competitors including CUTISS, Solsys Medical, Heartseed, ORTHOCON and Tissue Regenix, among others.
- Headquarter Morrisville, United States
- Employees 220 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Humacyte, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$148.7 M (USD)-34.24as on Dec 31, 2024
-
EBITDA
-$107.21 M (USD)-16.12as on Dec 31, 2024
-
Total Equity Funding
$424.76 M (USD)
in 11 rounds
-
Latest Funding Round
Not available
-
Investors
SVB
& 12 more
-
Employee Count
220
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Humacyte
Humacyte is a publicly listed company on the NASDAQ with ticker symbol HUMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Humacyte
Humacyte offers a comprehensive portfolio of products and services, including Symvess™ and Acellular Tissue Engineered Vessel (ATEV™).
Symvess™ is used for vascular trauma repair treatment.
ATEV™ is developed for hemodialysis arteriovenous access needs.
People of Humacyte
Unlock access to complete
Unlock access to complete
Funding Insights of Humacyte
Humacyte has successfully raised a total of $424.76M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Humacyte
Humacyte has secured backing from 13 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include SVB, Bangkok Bank and Fresenius Medical Care.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and holding company controlled by Len Blavatnik
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Biotech startups are incubated and funded in North Carolina.
|
Locked | Locked | Locked |
Investor details for Humacyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Humacyte
Investment portfolio details for Humacyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Humacyte
Detailed financials for Humacyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Humacyte Comparisons
Peer comparison for Humacyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Humacyte
Humacyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CUTISS, Solsys Medical, Heartseed, ORTHOCON and Tissue Regenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Personalized skin tissue therapy is developed by CUTISS for surgeries.
|
|
| Locked | Locked | Locked |
Human skin allografts and dressings for wound care are supplied.
|
|
| Locked | Locked | Locked |
Developer of myocardial regenerative medicine for treating heart diseases
|
|
| Locked | Locked | Locked |
Resorbable hemostatic bone putty is developed to stop surgical bleeding.
|
|
| Locked | Locked | Locked |
Developer of regenerative medical devices by using cell technology
|
Detailed competitors of Humacyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Humacyte
Complete news archive for Humacyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Humacyte
Humacyte was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Humacyte is headquartered in Morrisville, United States.
Humacyte is a funded company, having raised a total of $424.76M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Humacyte is 220.
Humacyte is engaged in the development and manufacture of bioengineered human tissues and organs. These tissues are designed to be universally implantable, off-the-shelf, and regenerative, targeting a wide range of diseases, injuries, and chronic conditions. The companys platform supports tissue repair and replacement across various clinical needs, including vascular trauma, hemodialysis access, and investigational applications like tracheal and esophageal replacement. Solutions are built on the Acellular Tissue Engineered Vessel platform, aiming for low infection rates and broad patient accessibility in the healthcare sector.
Humacyte's top competitors include CUTISS, Acera Surgical and Heartseed.
Humacyte offers Symvess™ and Acellular Tissue Engineered Vessel (ATEV™).
Yes, Humacyte is publicly traded on NASDAQ under the ticker symbol HUMA.
Humacyte has 13 investors. Key investors include SVB, Bangkok Bank, Fresenius Medical Care, HHS, and NCBiotech.
The ticker symbol of Humacyte is HUMA on NASDAQ.